^
    CANCER:

    Esophageal Cancer





    Show legend
    Group by Gene:
    Include preclinical:

    PD1 inhibitor
    nivolumab
    pembrolizumab
    sintilimab
    		0
    PD1 inhibitor
    tislelizumab
    toripalimab-tpzi
    camrelizumab
    zimberelimab
    dostarlimab-gxly
    serplulimab
    sugemalimab
    		1
    PD-L1 inhibitor
    atezolizumab
    durvalumab
    avelumab
    2
    PD1 inhibitor, CTLA4 inhibitor
    nivolumab + ipilimumab
    3
    VEGFR-2 inhibitor
    ramucirumab
    rivoceranib
    4
    DNA synthesis inhibitor, DNA cross linking agent, Thymidylate synthase inhibitor
    capecitabine + oxaliplatin
    5-fluorouracil + oxaliplatin
    5
    Thymidylate synthase inhibitor, Topoisomerase I inhibitor
    5-fluorouracil + irinotecan
    6
    Topoisomerase I inhibitor
    irinotecan
    7
    DNA synthesis inhibitor, DNA cross linking agent
    oxaliplatin
    EGFR inhibitor
    		8
    EGFR inhibitor
    erlotinib
    cetuximab
    nimotuzumab
    9
    TrkB receptor inhibitor, TrkC kinase inhibitor, TrkA receptor inhibitor
    larotrectinib
    10
    HER2 inhibitor, HER2 dimerization inhibitor
    trastuzumab + pertuzumab
    11
    DNA synthesis inhibitor
    cisplatin
    nedaplatin
    12
    HER2 inhibitor
    HER2 inhibitor
    trastuzumab
    13
    FGFR inhibitor
    pemigatinib
    14
    pan-HER inhibitor
    Z650
    15
    BTK inhibitor
    ibrutinib
    16
    HER2 exon 20 mutation inhibitor
    BI 1810631
    17
    VEGFR inhibitor, FGFR1 inhibitor, PD1 inhibitor
    toripalimab-tpzi + surufatinib
    18
    Tubulin polymerization promoter, Bcl2 inhibitor
    paclitaxel
    carboplatin + paclitaxel
    19
    CLDN18.2 inhibitor
    zolbetuximab
    20
    DKK1 protein inhibitor
    DKN-01
    21
    DKK1 protein inhibitor, PD1 inhibitor
    pembrolizumab + DKN-01
    22
    HER2 inhibitor, PD1 inhibitor
    pembrolizumab + trastuzumab
    nivolumab + trastuzumab
    23
    RET inhibitor
    selpercatinib
    24
    EGFR antagonist
    SCT200
    25
    MEK inhibitor, BRAF inhibitor
    trametinib + dabrafenib
    26
    HER3 inhibitor
    AV-203
    27
    PD-L1 inhibitor, HER2 inhibitor
    trastuzumab + avelumab
    28
    Microtubule inhibitor, EGFR-targeted antibody-drug conjugate
    MRG003
    LR004-VC-MMAE
    29
    PRMT5 inhibitor
    AMG 193
    30
    CCR4 receptor antagonist
    mogamulizumab-kpkc
    FP
    XP
    CaT
    IP
    		31
    Chemotherapy
    DP
    FLOT
    DOF
    TPF
    FOLFOX
    SOX
    32
    Immunotherapy
    Immunotherapy
    33
    DNA synthesis inhibitor, Thymidylate synthase inhibitor
    cisplatin + 5-fluorouracil
    34
    Microtubule stabilizer, Tubulin polymerization promoter
    docetaxel
    35
    Tubulin polymerization promoter, Bcl2 inhibitor, Thymidylate synthase inhibitor
    paclitaxel + capecitabine
    paclitaxel + 5-fluorouracil
    36
    Tubulin polymerization promoter, DNA synthesis inhibitor, Bcl2 inhibitor
    cisplatin + paclitaxel
    37
    PD-L1 inhibitor, CTLA4 inhibitor
    durvalumab + tremelimumab
    38
    Microtubule stabilizer, Tubulin polymerization promoter, Topoisomerase I inhibitor
    docetaxel + irinotecan
    39
    Microtubule stabilizer, Tubulin polymerization promoter, Thymidylate synthase inhibitor
    carboplatin + docetaxel + 5-fluorouracil
    40
    TrkB receptor inhibitor, TrkC kinase inhibitor, ROS1 inhibitor, TrkA receptor inhibitor, ALK inhibitor, JAK2 inhibitor, TNK2 inhibitor
    entrectinib
    41
    HER2 inhibitor, HER4 inhibitor, EGFR inhibitor
    afatinib
    42
    TIGIT inhibitor, PD1 inhibitor
    tislelizumab + BGB-A1217
    zimberelimab + AB154
    43
    B7-H3-targeted antibody-drug conjugate, Topoisomerase I inhibitor
    DS-7300
    44
    CLDN18.2 inhibitor, CD3 agonist
    AZD5863
    45
    MUC1-targeted antibody-drug conjugate, Microtubule inhibitor, EGFR-targeted antibody-drug conjugate
    M1231
    46
    PD-L1 inhibitor, TIGIT inhibitor
    atezolizumab + RG6058
    47
    HER2-targeted antibody-drug conjugate, Topoisomerase I inhibitor
    fam-trastuzumab deruxtecan-nxki
    48
    mTORC1 inhibitor
    nanoparticle albumin-bound rapamycin
    49
    Multi-tyrosine kinase inhibitor
    anlotinib
    50
    Aurora kinase A inhibitor
    MLN8237
    51
    C4.4a-targeted antibody-drug conjugate, Microtubule inhibitor
    BAY1129980
    52
    MAT2A inhibitor
    IDE397
    53
    HER2 inhibitor, HER4 inhibitor, CDK4 inhibitor, EGFR inhibitor, CDK6 inhibitor
    palbociclib + neratinib
    54
    p53 reactivator
    APR-246
    55
    CDK9 inhibitor
    KB-0742
    56
    AMPK activator
    metformin
    57
    YES1 inhibitor, Src kinase inhibitor
    NXP900
    58
    KRAS G12C inhibitor
    RG6330
    59
    Tubulin polymerization promoter
    carboplatin
    60
    GPC-1-targeted antibody-drug conjugate
    anti-GPC-1 ADC
    No biomarker
    HER-2 negative
    HER-2 positive
    HER-2 overexpression
    HER-2 amplification
    HER-2 mutation
    PD-L1 expression
    PD-L1 overexpression
    PD-L1 underexpression
    MSI-H/dMMR
    EGFR overexpression
    EGFR amplification
    EGFR expression
    EGFR mutation
    EGFR L861Q
    DKK1 overexpression
    NTRK3 fusion
    CLDN18.2 expression
    IFNG overexpression
    FGFR1 mutation
    LGALS1 elevation
    LAMP3-L
    FGFR1 A354V
    LAMP3 overexpression
    LGALS1 underexpression
    IFNG-L
    CD73 underexpression
    KDR expression
    NFKB1 expression
    CD276 overexpression
    ARID1A mutation
    CXCL5 overexpression
    CCL19 underexpression
    UMODL1 underexpression
    GRB7 positive
    TMB-H
    ERCC1 negative
    TTN D7145H
    MYH4 Q1210fs
    PD-L1 overexpression + CCL5 overexpression
    TP53 mutation
    COL19A1 overexpression
    FOXP3 overexpression
    MUC1 expression + EGFR expression
    SDC1 expression
    MYC amplification
    LDH elevation
    CCR4 negative
    MTAP deletion
    TIGIT expression
    BRAF V600E
    MSI-H/dMMR + MLH1 deletion + PMS2 deletion
    BRCA1 mutation
    RET fusion
    HER-2 negative + PD-L1 expression
    NTRK1 fusion
    NTRK2 fusion
    CD8 expression
    PD-1 expression
    SLFN11 expression
    NRG1 overexpression
    TLR signature
    PD-1 expression + CD8 expression
    NDRG1 overexpression
    GPC1 expression
    ERBB4 G1109C
    AURKA overexpression
    CDK14 overexpression
    SOX17 overexpression
    CD44 overexpression + CD24 underexpression
    UBQLN4 overexpression
    MACC1-AS1 overexpression
    PARP1 expression
    BRCA2 mutation
    LYPD3 expression
    CD31 expression
    BAX expression
    SOX9 overexpression
    HSPA6 expression
    PER2 underexpression
    YES1 amplification
    SGK1 overexpression
    MRE11A underexpression
    AFAP1-AS1 overexpression